Functional consequences of naturally occurring mutations in human uroporphyrinogen decarboxylase

Blood

Volumn 98, Issue 12, 2001, Pages 3179-3185

  Phillips, John D ^a   Parker, Tiffany L ^a   Schubert, Heidi L ^a   Whitby, Frank G ^a   Hill, Christopher P ^a   Kushner, James P ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; UROPORPHYRINOGEN DECARBOXYLASE;

ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; ENZYME ACTIVITY; EPSTEIN BARR VIRUS; FRAMESHIFT MUTATION; GENE MUTATION; HUMAN; HUMAN CELL; MISSENSE MUTATION; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN EXPRESSION; UNITED STATES;

EID: 0035760901     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.12.3179     Document Type: Article

References (35)

1. Wyckoff EE, Kushner JP. Heme biosynthesis, the porphyrias, and the liver. In: Arias IM, Boyer JL, Fausto N, Jakoby WB, Schachter DA, Shafritz DA, eds. The Liver: Biology and Pathobiology. 3rd ed. New York, NY: Raven Press; 1994:505-527.
2. Kappas A, Sassa S, Galbraith RA, Nordmann Y. The porphyrias. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. Vol 2, 7th ed. New York, NY: McGraw-Hill; 1995:2103-2160.
3. Moran-Jimenez MJ, Ged C, Romana M, et al. Uroporphyrinogen decarboxylase: complete human gene sequence and molecular study of three families with hepatoerythropoietic porphyria. Am J Hum Genet. 1996;58:712-721.
4. Meguro K, Fujita H, Ishida N, et al. Molecular defects of uroporphyrinogen decarboxylase in a patient with mild hepatoerythropoietic porphyria. J Invest Dermatol. 1994;102:681-685.
5. de Verneuil H, Grandchamp B, Beaumont C, Picat C, Nordmann Y, Uroporphyrinogen decarboxylase structural mutant (Gly281→Glu) in a case of porphyria. Science. 1986;234:732-734.
6. Romana M, Grandchamp B, Dubart A, et al. Identification of a new mutation responsible for hepatoerythropoietic porphyria. Eur J Clin Invest. 1991;21:225-229.
7. Garey JR, Hansen JL, Harrison LM, Kennedy JB, Kushner JP. A point mutation in the coding region of uroporphyrinogen decarboxylase associated with familial porphyria cutanea tarda. Blood. 1989;73:892-895.
8. Garey JR, Franklin KF, Brown DA, et al. Analysis of uroporphyrinogen decarboxylase complementary DNAs in sporadic porphyria cutanea tarda. Gastroenterology. 1993;105:165-169.
9. McManus JF, Begley CG, Sassa S, Ratnaike S. Five new mutations in the uroporphyrinogen decarboxylase gene identified in families with cutaneous porphyria. Blood. 1996;88:3589-3600.
10. Christiansen L, Ged C, Hombrados I, et al. Screening for mutations in the uroporphyrinogen decarboxylase gene using denaturing gradient gel electrophoresis: identification and characterization of six novel mutations associated with familial PCT. Hum Mutat. 1999;14:222-232.
11. McManus JF, Begley CG, Sassa S, Ratnaike S. Three new mutations in the uroporphyrinogen decarboxylase gene in familial porphyria cutanea tarda [abstract]. Hum Mutat. 1999;13:412.
12. Brady JJ, Jackson HA, Roberts AG, et al. Coinheritance of mutations in the uroporphyrinogen decarboxylase and hemochromatosis genes accelerates the onset of porphyria cutanea tarda. J Invest Dermatol. 2000;115:868-874.
13. Mendez M, Sorkin L, Rossetti MV, et al. Familial porphyria cutanea tarda: characterization of seven novel uroporphyrinogen decarboxylase mutations and frequency of common hemochromatosis alleles. Am J Hum Genet. 1998;63:1363-1375.
14. Mendez M, Rossetti MV, Siervi AD, del Carmen Batlie AM, Parera V. Mutations in familial porphyria cutanea tarda: two novel and two previously described for hepatoerythropoietic porphyria. Hum Mutat. 2000;16:269-270.
15. Bulaj ZJ, Phillips JD, Ajioka RS, et al. Hemochromatosis genes and other factors contributing to the pathogenesis of porphyria cutanea tarda. Blood. 2000;95:1565-1571.
16. Bonkovsky HL, Poh-Fitzpatrick M, Pimstone N, et al. Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in North America. Hepatology. 1998;27:1661-1669.
17. Phillips JD, Whitby FG, Kushner JP, Hill CP. Characterization and crystallization of human uroporphyrinogen decarboxylase. Protein Sci. 1997;6:1343-1346.
18. McLellan T, Pryor MA, Kushner JP, Eddy RL, Shows TB. Assignment of uroporphyrinogen decarboxylase (UROD) to the pter-p21 region of human chromosome 1. Cytogenet Cell Genet. 1985;39:224-227.
19. Dubart A, Mattei MG, Raich N, et al. Assignment of human uroporphyrinogen decarboxylase (URO-D) to the p34 band of chromosome 1. Hum Genet. 1986;73:277-279.
20. Romana M, Dubart A, Beaupain D, et al. Structure of the gene for uroporphyrinogen decarboxylase. Nucleic Acids Res. 1987;15:7343-7356.
21. Whitby FG, Phillips JD, Kushner JP, Hill CP. Crystal structure of human uroporphyrinogen decarboxylase. EMBO J. 1998;17:2463-2471.
22. Ford RE, Ou CN, Ellefson RD. Liquid-chromatographic analysis for urinary porphyrins. Clin Chem. 1981;27:397-401.
23. Phillips JD, Kushner JP. Measurement of uroporphyrinogen decarboxylase activity. In: Maines MD, Costa LG, Reed DJ, Sassa S, Sipes IG, eds. Current Protocols in Toxicology. New York, NY: John Wiley & Sons; 1999:8.4.1-8.4.13.
24. Otwinowski Z, Minor W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 1997;276:307-326.
25. Brunger A. X-PLOR: A System for X-ray Crystallography and NMR. New Haven, CT: Yale University Press; 1996
26. Jones TA, Zou JY, Cowan SW, Kjeldgaard M. Improved methods for binding protein models in electron density maps and the location of errors in these models. Acta Crystallogr A. 1991;47:110-119.
27. Pelloquin F, Lamelin JP, Lenoir GM. Human B lymphocytes immortalization by Epstein-Barr virus in the presence of cyclosporin A. In Vitro Cell Dev Biol. 1986;22:689-694.
28. Hansen JL, Pryor MA, Kennedy JB, Kushner JP. Steady-state levels of uroporphyrinogen decarboxylase mRNA in lymphoblastoid cell lines from patients with familial porphyria cutanea tarda and their relatives. Am J Hum Genet. 1988;42:847-853.
29. Seeling JM, Miller JR, Gil R, et al. Regulation of beta-catenin signaling by the B56 subunit of protein phosphatase 2A. Science. 1999;283:2089-2091.
30. Garey JR, Harrison LM, Franklin KF, et al. Uroporphyrinogen decarboxylase: a splice site mutation causes the deletion of exon 6 in multiple families with porphyria cutanea tarda. J Clin Invest. 1990;86:1416-1422.
31. Brawerman G. mRNA decay: finding the right targets. Cell. 1989;57:9-10.
32. Frischmeyer PA, Dietz HC. Nonsense-mediated mRNA decay in health and disease. Hum Mol Genet. 1999;8:1893-1900.
33. Phillips JD, Jackson LK, Bunting M, et al. A mouse model of familial porphyria cutanea tarda. Proc Natl Acad Sci U S A. 2001;98:259-264.
34. Elder GH, Lee GB, Tovey JA. Decreased activity of hepatic uroporphyrinogen decarboxylase in sporadic porphyria cutanea tarda. N Engl J Med. 1978;299:274-278.
35. Elder GH, Urquhart AJ, De Salamanca RE, Munzo JJ, Bonkovsky HL. Immunoreactive uroporphyrinogen decarboxylase in the liver in porphyria cutanea tarda. Lancet. 1985;11:229-232.